Clinical trial NCT06965231: Perioperative Toripalimab and Endostatin for Stage II Melanoma: A Phase II Trial
Official title: Efficacy and Safety of Perioperative Toripalimab Combined With Recombinant Human Endostatin as Postoperative Adjuvant Therapy for Clinical Stage II Malignant Melanoma: A Multicenter, Single-Arm, Phase II Clinical Study
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: PHASE2
Conditions: Melanoma of Skin
Acral Melanoma
Stage II Melanoma
Keywords: Melanoma of skin
Acral melanoma
Stage II melanoma
Toripalimab
Recombinant human endostatin (Endostar)
Perioperative immunotherapy
PD-1 inhibitor
Anti-angiogenic therapy
Phase II study
Lead sponsor: Fudan University
Sponsor class: OTHER
Collaborators: name: Fudan University Shanghai Cancer Center Minhang Branch Hospital
name: Shanghai Tongren Hospital, Shanghai Jiao Tong University School of Medicine
name: Shanghai 411 hospital
First posted: 2025-05-11
Enrollment: 58
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: This is a Phase II clinical trial to evaluate the efficacy and safety of perioperative toripalimab (anti-PD-1) combined with recombinant human endostatin (Endostar) as postoperative adjuvant therapy in patients with clinical stage II cutaneous or acral malignant melanoma. The study aims to answer:

1. Does this combination improve the 2-year recurrence-free survival (2y-RFS) compared to historical data?
2. Is the treatment safe and tolerable for patients?

Participants will:

1. Receive 2 cycles of toripalimab before surgery (neoadjuvant therapy).
2. Undergo surgical removal of the tumor.
3. Post surgery, receive toripalimab every 2 weeks + Endostar (72-hour continuous infusion every 4 weeks) for up to 6 cycles (Endostar) or 11 cycles (toripalimab).
4. Be monitored for tumor recurrence, side effects, and survival for up to 2 years after treatment.

This is a single-arm, multicenter study involving 58 patients across several hospitals in China. Results will help determine if this combination could become a new standard adjuvant therapy for stage II melanoma.


Eligibility criteria: Inclusion Criteria:

1. Age ≥ 18 years, regardless of gender;
2. ECOG performance status: 0-1;
3. Patients with histologically or cytologically confirmed cutaneous or acral malignant melanoma, excluding mucosal and uveal melanoma;
4. Patients with BRAF, CKIT, and NRAS gene test results;
5. Treatment-naïve patients who have not received prior anti-tumor therapy;
6. Clinical stage II (AJCC 8th edition, 2017);
7. Laboratory tests must meet the following criteria:

   1. Hematology: Hemoglobin (Hb) ≥90 g/L (no transfusion within 14 days); absolute neutrophil count (ANC) ≥1.5×10\^9/L; platelet count (PLT) ≥100×10\^9/L;
   2. Biochemistry: Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤2.5×ULN; total bilirubin (TBIL) ≤1.5×ULN; serum creatinine (Cr) ≤1.5×ULN, and creatinine clearance \>50 μmol/L;
   3. Coagulation: Activated partial thromboplastin time (APTT), international normalized ratio (INR), and prothrombin time (PT) ≤1.5×ULN;
   4. Doppler ultrasound assessment: Left ventricular ejection fraction (LVEF) ≥50%;
8. Female patients must agree to use contraception (e.g., intrauterine device \[IUD\], oral contraceptives, or condoms) during the study and for 6 months after study completion. A negative serum or urine pregnancy test within 7 days before enrollment is required, and patients must be non-lactating. Male patients must agree to use contraception during the study and for 6 months after study completion;
9. Patients must voluntarily participate in the study, sign the informed consent form, and demonstrate good compliance.

Exclusion Criteria:

1. History of allergic reactions to biological products;
2. Patients with prior or concurrent malignancies within 5 years (except cured basal cell carcinoma of skin or carcinoma in situ of cervix);
3. Any active autoimmune disease or history of autoimmune disorders (including but not limited to: autoimmune hepatitis, interstitial pneumonia, enteritis, vasculitis, nephritis; asthma requiring bronchodilators for medical intervention). Exceptions include: vitiligo, psoriasis, alopecia not requiring systemic therapy, well-controlled type I diabetes, or hypothyroidism with normal thyroid function on replacement therapy;
4. Requirement for immunosuppressive therapy using systemic or absorbable topical corticosteroids (equivalent to prednisone \>10mg/day) within 2 weeks prior to first dose;
5. Any history or evidence of bleeding diathesis regardless of severity; grade ≥3 bleeding events per CTCAE v5.0 within 4 weeks prior to first dose; or presence of unhealed wounds, fractures, active gastrointestinal ulcers, ulcerative colitis, tumors with active bleeding, or other conditions deemed by investigators to potentially cause gastrointestinal hemorrhage or perforation;
6. Patients with severe and/or uncontrolled comorbidities including:

   1. Poorly controlled hypertension (SBP ≥150 mmHg or DBP ≥90 mmHg);
   2. Unstable angina, myocardial infarction, ≥grade 2 congestive heart failure, or arrhythmias requiring treatment (including QTc ≥480ms) within 6 months prior to first dose;
   3. Active or uncontrolled severe infections (≥grade 2 per CTCAE);
   4. Clinically significant liver disease including viral hepatitis (active HBV infection with HBV DNA \>1×10³ copies/mL or \>500 IU/mL; HCV infection with HCV RNA \>1×10³ copies/mL or \>100 IU/mL), decompensated liver disease, or chronic hepatitis requiring antiviral therapy;
   5. HIV-positive status;
   6. Poorly controlled diabetes (fasting glucose ≥grade 2 per CTCAE);
   7. Urinalysis showing proteinuria ≥++ with 24-hour urinary protein \>1.0 g;
7. Administration of live vaccines within 4 weeks prior to treatment or anticipated need during study;
8. Other conditions deemed by investigators to potentially lead to premature study termination, including: severe comorbidities (including psychiatric disorders) requiring concomitant therapy, significant laboratory abnormalities, or social/family factors that may compromise patient safety or data/sample collection.

Primary outcomes:
measure: 2-year recurrence-free survival rate (2-year RFS rate)
timeFrame: From enrollment to the end of the 2nd year of follow-up
Secondary outcomes:
measure: 1-year distant metastasis-free survival rate (1-year DMFS rate)
timeFrame: From enrollment to the end of the 1st year
measure: Overall survival (OS)
timeFrame: Through study completion, an average of 3 years
measure: 1-year recurrence-free survival rate (1-year RFS rate)
timeFrame: From enrollment to the end of the 1st year
measure: 2-year distant metastasis-free survival rate (2-year DMFS rate)
timeFrame: From enrollment to the end of the 2nd year
Other outcomes:
Locations:
city: Shanghai
country: China
facility: Department of Musculoskeletal Oncology, Fudan University Shanghai Cancer Center
state: Shanghai
city: Shanghai
country: China
facility: Cancer center, Shanghai 411 hospital, China RongTong Medical Healthcare Group Co.Ltd./411 Hospital, Shanghai University
state: Shanghai
city: Shanghai
country: China
facility: Department of Surgical Oncology, Fudan University Shanghai Cancer Center Minhang Branch Hospital
state: Shanghai
city: Shanghai
country: China
facility: Department of Oncology, Tongren Hospital, Shanghai Jiao Tong University School of Medicine
state: Shanghai
Study officials:
affiliation: Fudan University
name: Chunmeng Wang, Dr.
role: PRINCIPAL_INVESTIGATOR
References: